Atamyo Therapeutics

Atamyo Therapeutics is a leading biotechnology company focused on developing innovative gene therapies for neuromuscular diseases, dedicated to enhancing the lives of patients. A spin-off of the esteemed gene therapy pioneer Genethon, Atamyo Therapeutics harnesses unparalleled expertise in AAV-based gene therapy and muscular dystrophies. Atamyo Therapeutics’ advanced programs target various forms of limb-girdle muscular dystrophies (LGMD). With its primary address in Evry, 91000, FR, and a presence in Paris, FR, Atamyo Therapeutics is committed to providing life-long efficient treatments for neuromuscular conditions.

Atamyo Therapeutics leverages its deep understanding of gene therapy to pioneer breakthroughs in treating debilitating muscular conditions. The company’s commitment to innovation and patient care positions Atamyo Therapeutics as a key player in the biotechnology sector. Atamyo Therapeutics aims to transform the treatment landscape for neuromuscular diseases, offering hope and improved quality of life for patients worldwide.

Atamyo Therapeutics is dedicated to advancing the field of gene therapy and making a significant impact on the lives of those affected by neuromuscular disorders. The company’s strategic focus and expert team drive its mission to develop safe and effective treatments. We invite the management of Atamyo Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.